A3Access Advisors, LLC

Market Access Mindset: Are you taking the right steps in pricing your medicine(s)? Pricing plays a crucial role in the success of every pharmaceutical product launch. It is essential to carefully consider the needs of various stakeholders, including payers, physicians, other providers, patients, as well as investors. Without a sophisticated pricing strategy, a BioPharma company risks damaging its reputation, facing payer restrictions, and failing to maximize revenue potential.   To set the right price for a new medicine, several key actions are critical: -     Establish how the new therapy compares to standard of care along clinical, economic, and humanistic outcomes -     Engage payers early to assess how the medicine profile resonates -     Identify relevant analogs to understand current market prices both list and net -     Determine how discounts and price impact access and utilization -     Assess the health economic impact of the new therapy along a range of different price points -     Develop a payer focused budget impact model to estimate the overall impact to total cost of care  -     Involve a senior cross-functional team in the final price decision  -     Ensure internal understanding and effective communication of the price to stakeholders By following these steps and adopting a comprehensive approach, companies can help ensure a successful medicine launch. A3Access offers expertise in pricing new medicines effectively and can provide valuable guidance. Reach out for assistance in navigating the complexities of pricing and determining the best price for your medicine.  #PricingStrategy #BioPharma #PatientAccess #A3Access #MarketAccessMindset

A3Access is pleased to announce the addition of Steve Henck to its leadership team as a partner in its strategic market access consulting practice. Steve brings a wealth of experience having previously led Channel and Payer Teams at Genentech and as a former executive at Cardinal Health. Steve’s work has encompassed strategy development and field execution within many account segments.   Steve’s expertise includes 25 years of hands-on, broad leadership in market access and emerging healthcare markets.  He is an expert in the business of pharmaceutical medicine commercialization. Steve has worked in Oncology, Hematology, Neurology, Rare Disease, Ophthalmology and Immunotherapy within all provider and channel related segments: ·      Developing and executing patient access strategies to enhance the patient experience ·      Navigating complex systems to optimize medicine access, sales, and reimbursement ·      Analyzing competitive market dynamics and payer environments to drive broad access and successful pull-thru ·      Understanding provider economics and incorporating this knowledge into robust account strategies for medicines reimbursed through both pharmacy and medical benefits   Steve’s accomplishments in sales, medicine launches, reimbursement, business retention, and strategic account management make him an excellent addition to the A3Access team.

Market Access Mindset – Is the price, right? Pricing new medicines is a critical and time-consuming process. It stands as one of the most important decisions a company makes. Drug prices face constant scrutiny and criticism from various stakeholders along the value chain, including the media and politicians. The complexity of the US healthcare system, with its multiple stakeholders and diverse financial incentives, adds further layers of challenge. Achieving the right price demands thoughtful considerations and a strategic approach. Despite this, many companies struggle to navigate this process effectively. Several key factors contribute to the mistakes many companies make when pricing new medicines: ·      Absence of a common set of organizational pricing principles ·      Inconsistent framework/methodology for pricing decisions ·      Deciding a price without knowledge of the final label ·      Failure to consider the perspective of all stakeholders' who influence adoption ·      Over indexing on physician/provider input ·      Not understanding how out-of-pocket costs impact patient access and affordability ·      Not accounting for competitive responses to your price ·      Ignoring the impact of mandatory and discretionary discounts on net price ·      Not considering for future indications with different price points based on their unique value propositions ·      Not anticipating how “real-world” dosing, adherence and compliance will impact utilization and price ·      Failure to effectively and confidently communicate your price and value proposition To overcome these challenges, it is essential to adopt a structured and comprehensive pricing framework. A3Access has a proven track record in pricing medicines effectively. If your organization is seeking guidance in navigating the complexities of pricing new medicines, we are here to help. Let's work together to secure a pricing strategy that instills confidence and drives commercial success. [email protected] #BioPharmaceuticals #DrugPricingStrategy #A3Access #MedicinePricing #marketaccessmindset #Patientaccess

On Saturday, A3Access Advisors, LLC braved the wind, rain, and cold at Crissy Field to participate in the Parkinson’s Moving Day Walk. This 5K walk allowed us to show our support for the Parkinson's Foundation, patients and caregivers impacted by this troubling disease. Our goal was to find a small way to contribute in helping this community find a cure for this severely debilitating disease which currently impacts one million people in the US, and the 90,000 more that will be diagnosed this year. Thanks to the Parkinson’s Foundation for sponsoring such a fun and worthy event. #giveback #a3access #movingday #biopharma #parkinsonsdisease

There is still time to respond and share your thoughts.

At A3Access Advisors, LLC we would love to learn about your biggest market access challenges. Take a couple of minutes and check out our latest poll and share your thoughts. Alternatively, check out our website and reach out to us directly. #marketaccessmindset #biotech #commercialsuccess

There are many reasons why innovative medicines fail to achieve their commercial objectives. One of the most common reasons is a lack of preparation and readiness to address market access opportunities and challenges. 

4 reasons to meet with A3Access at Asembia: 1. Learn what we have been doing to help our clients. 2. Talk about your most pressing market access issues and how we can help. 3. Discuss your latest innovations and capability enhancements. 4. And why not? We will all be there anyway! Join us at Asembia24 to explore these opportunities and more. #marketaccessmindset #biotechnology #pharma #asembia24

We recently launched our new website. Please check it out and see how we can help with your market access opportunities and challenges on route to accelerating adoption to your innovative medicines. www.a3access.com

Come join us in person, in spirit, or via your contributions. Everyone can help make a difference in changing the course of this devastating disease.